FDA approval fuels Boehringer’s biosimilar challenge to AbbVie’s Humira
Yesterday Boehringer Ingelheim won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.
If you are not happy with the results below please do another search
Yesterday Boehringer Ingelheim won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.
Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans.
Novo Nordisk (NOVOb.CO) has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have increased, a senior executive said.
Apart from an impact of about $40 million cut in inventory, Regeneron said changing market dynamics that resulted in lower volumes and lower selling price also hurt eye drug Eylea sales.
Citing a strategic prioritization by Moderna, Metagenomi announced that the partners have “mutually agreed” to terminate their gene editing agreement.
The collaboration is designed to combine “the innovative cell therapy platforms from each of the companies,” according to the announcement.
Healthcare and drug industry groups on Wednesday urged a U.S. appeals court to revive their challenge to a law requiring manufacturers to negotiate the prices of some drugs with the U.S government’s Medicare health insurance program or pay heavy penalties.
Dedicated to the growth and development of Peregrine, Schmid has been elevated to partner, and Deng was promoted to senior content strategist, with the responsibility of leading projects in collaboration with an interdepartmental team of strategists, copywriters, art directors, and account service representatives to help clients identify opportunities for managed market–focused content development.
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their patents.
Neurocrine Biosciences won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.